In this Expert Interview, Dr. Andrew D. Seidman critically appraises the latest data, addresses the controversies, and opines about adjuvant systemic therapy for breast cancer. Medscape Hematology-Oncology
An FDA review launched in the wake of a controversial 2010 meta-analysis has concluded that the drugs do not pose a cancer risk to patients. The FDA says it conducted a much larger, more comprehensive review of the data to reach its reassuring conclusions. Not everyone, however, is satisfied. br / iHeartwire/i
Dr. Mark Kris highlights the therapeutic benefits -- and toxicities -- associated with bevacizumab use in patients with non-small cell lung cancer. Medscape Hematology-Oncology
